Investigate how microglial senescence drives ALS progression through inflammation, trophic support loss, and protein aggregation. Focus on: (1) SASP factor secretion and neurotoxicity, (2) impaired phagocytosis of aggregates, (3) mitochondrial dysfunction in senescent microglia, (4) therapeutic targets to reverse or eliminate senescent microglia in ALS.
This hypothesis proposes that TBK1 loss-of-function mutations initiate a pathological cascade where microglia become locked in a senescent state, secreting MMP-9 via the senescence-associated secretory phenotype (SASP), which then generates pathological TDP-43 C-terminal fragments that propagate ALS pathology. The mechanism begins with TBK1 haploinsufficiency disrupting normal microglial homeostasis through impaired NF-κB/IRF3 signaling and defective autophagy, forcing microglia into a senescent, pro-inflammatory state. These senescent microglia then upregulate and secrete MMP-9 as a key SASP component, creating a localized proteolytic environment around motor neurons.
...
This hypothesis proposes that TBK1 loss-of-function mutations initiate a pathological cascade where microglia become locked in a senescent state, secreting MMP-9 via the senescence-associated secretory phenotype (SASP), which then generates pathological TDP-43 C-terminal fragments that propagate ALS pathology. The mechanism begins with TBK1 haploinsufficiency disrupting normal microglial homeostasis through impaired NF-κB/IRF3 signaling and defective autophagy, forcing microglia into a senescent, pro-inflammatory state. These senescent microglia then upregulate and secrete MMP-9 as a key SASP component, creating a localized proteolytic environment around motor neurons. The secreted MMP-9 cleaves TDP-43, generating C-terminal fragments that readily aggregate in the cytoplasm and seed further pathological spread. This model explains how genetic TBK1 mutations can initiate ALS pathogenesis through a two-step process: first creating the inflammatory microenvironment via microglial senescence, then generating the specific molecular pathology through MMP-9-mediated TDP-43 fragmentation. The hypothesis predicts that TBK1-deficient microglia will show elevated MMP-9 expression concurrent with senescence markers, and that MMP-9 inhibition should rescue TDP-43 pathology specifically in TBK1-haploinsufficient contexts. This mechanism reconciles why TBK1 mutations cause familial ALS while also explaining the generation of pathological TDP-43 species that characterize sporadic disease, positioning TBK1 loss as an upstream driver of the microglial dysfunction that generates downstream TDP-43 pathology.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["dsDNA/dsRNA or Bacteria STING/MAVS Signal"]
B["TBK1 Activation IKK-epsilon Complex"]
C["IRF3 Phosphorylation Ser396 by TBK1"]
D["IRF3 Dimerization Nuclear Import"]
E["Type-I IFN Expression IFN-beta/IFN-alpha"]
F["Antiviral Defense ISG Upregulation"]
G["TBK1 Loss-of-Function ALS10 Mutations"]
H["OPTN/p62 Phosphorylation Selective Autophagy"]
A --> B
B --> C
B --> H
C --> D
D --> E
E --> F
G -.->|"impairs"| B
G -.->|"impairs"| H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for TBK1 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
Manganelli F et al., Cells 2026 Mar 6 · PMID:41827910
No claimMODERATE
Smeyers J et al., Cell Rep 2025 Nov 25 · PMID:41171761
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Scientific Skeptic Assessment: TBK1 Loss/Microglial Senescence Hypothesis in ALS
Executive Summary
The hypothesis proposes a coherent and mechanistically plausible model linking TBK1 loss-of-function mutations to ALS pathogenesis through microglial senescence and SASP. While supported by compelling animal model data and consistent with known roles for TBK1 in inflammatory signaling, this framework faces significant challenges from the prevailing evidence suggesting neuronal autophagy dysfunction as the primary TBK1-dependent pathogenic mechanism. I identify critical gaps in causal evi
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Scientific Synthesis: TBK1 Loss/Microglial Senescence Hypothesis in ALS
Integration of Prior Arguments
The Core Tension
The debate crystallizes around a fundamental question: Is the primary TBK1 pathogenic axis neuronal (autophagy/proteostasis) or microglial (senescence/SASP)?
The Theorist presents compelling circumstantial evidence: microglia-specific TBK1 deletion reproduces aged transcriptional signatures, RIPK1-driven inflammation emerges from TBK1 insufficiency, and cGAS-STING activation downstream provides mechanistic plausibility. The Skeptic counters with pho
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.